These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1980 related articles for article (PubMed ID: 18840786)

  • 1. Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice.
    Xu J; Lloyd DJ; Hale C; Stanislaus S; Chen M; Sivits G; Vonderfecht S; Hecht R; Li YS; Lindberg RA; Chen JL; Jung DY; Zhang Z; Ko HJ; Kim JK; Véniant MM
    Diabetes; 2009 Jan; 58(1):250-9. PubMed ID: 18840786
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fibroblast growth factor 21 action in the brain increases energy expenditure and insulin sensitivity in obese rats.
    Sarruf DA; Thaler JP; Morton GJ; German J; Fischer JD; Ogimoto K; Schwartz MW
    Diabetes; 2010 Jul; 59(7):1817-24. PubMed ID: 20357365
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fibroblast growth factor 21 corrects obesity in mice.
    Coskun T; Bina HA; Schneider MA; Dunbar JD; Hu CC; Chen Y; Moller DE; Kharitonenkov A
    Endocrinology; 2008 Dec; 149(12):6018-27. PubMed ID: 18687777
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatic SIRT1 attenuates hepatic steatosis and controls energy balance in mice by inducing fibroblast growth factor 21.
    Li Y; Wong K; Giles A; Jiang J; Lee JW; Adams AC; Kharitonenkov A; Yang Q; Gao B; Guarente L; Zang M
    Gastroenterology; 2014 Feb; 146(2):539-49.e7. PubMed ID: 24184811
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lack of overt FGF21 resistance in two mouse models of obesity and insulin resistance.
    Hale C; Chen MM; Stanislaus S; Chinookoswong N; Hager T; Wang M; Véniant MM; Xu J
    Endocrinology; 2012 Jan; 153(1):69-80. PubMed ID: 22067317
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rhein ameliorates fatty liver disease through negative energy balance, hepatic lipogenic regulation, and immunomodulation in diet-induced obese mice.
    Sheng X; Wang M; Lu M; Xi B; Sheng H; Zang YQ
    Am J Physiol Endocrinol Metab; 2011 May; 300(5):E886-93. PubMed ID: 21364120
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute glucose-lowering and insulin-sensitizing action of FGF21 in insulin-resistant mouse models--association with liver and adipose tissue effects.
    Xu J; Stanislaus S; Chinookoswong N; Lau YY; Hager T; Patel J; Ge H; Weiszmann J; Lu SC; Graham M; Busby J; Hecht R; Li YS; Li Y; Lindberg R; Véniant MM
    Am J Physiol Endocrinol Metab; 2009 Nov; 297(5):E1105-14. PubMed ID: 19706786
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Naringenin prevents obesity, hepatic steatosis, and glucose intolerance in male mice independent of fibroblast growth factor 21.
    Assini JM; Mulvihill EE; Burke AC; Sutherland BG; Telford DE; Chhoker SS; Sawyez CG; Drangova M; Adams AC; Kharitonenkov A; Pin CL; Huff MW
    Endocrinology; 2015 Jun; 156(6):2087-102. PubMed ID: 25774553
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined effects of rosiglitazone and conjugated linoleic acid on adiposity, insulin sensitivity, and hepatic steatosis in high-fat-fed mice.
    Liu LF; Purushotham A; Wendel AA; Belury MA
    Am J Physiol Gastrointest Liver Physiol; 2007 Jun; 292(6):G1671-82. PubMed ID: 17322064
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatic insulin resistance and increased hepatic glucose production in mice lacking Fgf21.
    Camporez JP; Asrih M; Zhang D; Kahn M; Samuel VT; Jurczak MJ; Jornayvaz FR
    J Endocrinol; 2015 Sep; 226(3):207-17. PubMed ID: 26203166
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum fibroblast growth factor 21 in human obesity: regulation by insulin infusion and relationship with glucose and lipid oxidation.
    Strączkowski M; Karczewska-Kupczewska M; Adamska A; Otziomek E; Kowalska I; Nikołajuk A
    Int J Obes (Lond); 2013 Oct; 37(10):1386-90. PubMed ID: 23419601
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fibroblast growth factor 21 increases hepatic oxidative capacity but not physical activity or energy expenditure in hepatic peroxisome proliferator-activated receptor γ coactivator-1α-deficient mice.
    Fletcher JA; Linden MA; Sheldon RD; Meers GM; Morris EM; Butterfield A; Perfield JW; Rector RS; Thyfault JP
    Exp Physiol; 2018 Mar; 103(3):408-418. PubMed ID: 29215172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevention and reversal of hepatic steatosis with a high-protein diet in mice.
    Garcia-Caraballo SC; Comhair TM; Verheyen F; Gaemers I; Schaap FG; Houten SM; Hakvoort TB; Dejong CH; Lamers WH; Koehler SE
    Biochim Biophys Acta; 2013 May; 1832(5):685-95. PubMed ID: 23410526
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pegylated Fgf21 rapidly normalizes insulin-stimulated glucose utilization in diet-induced insulin resistant mice.
    Camacho RC; Zafian PT; Achanfuo-Yeboah J; Manibusan A; Berger JP
    Eur J Pharmacol; 2013 Sep; 715(1-3):41-5. PubMed ID: 23831019
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SGLT2 inhibition reprograms systemic metabolism via FGF21-dependent and -independent mechanisms.
    Osataphan S; Macchi C; Singhal G; Chimene-Weiss J; Sales V; Kozuka C; Dreyfuss JM; Pan H; Tangcharoenpaisan Y; Morningstar J; Gerszten R; Patti ME
    JCI Insight; 2019 Mar; 4(5):. PubMed ID: 30843877
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Spironolactone improves glucose and lipid metabolism by ameliorating hepatic steatosis and inflammation and suppressing enhanced gluconeogenesis induced by high-fat and high-fructose diet.
    Wada T; Kenmochi H; Miyashita Y; Sasaki M; Ojima M; Sasahara M; Koya D; Tsuneki H; Sasaoka T
    Endocrinology; 2010 May; 151(5):2040-9. PubMed ID: 20211973
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dietary capsaicin reduces obesity-induced insulin resistance and hepatic steatosis in obese mice fed a high-fat diet.
    Kang JH; Goto T; Han IS; Kawada T; Kim YM; Yu R
    Obesity (Silver Spring); 2010 Apr; 18(4):780-7. PubMed ID: 19798065
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endogenous interleukin-10 protects against hepatic steatosis but does not improve insulin sensitivity during high-fat feeding in mice.
    den Boer MA; Voshol PJ; Schröder-van der Elst JP; Korsheninnikova E; Ouwens DM; Kuipers F; Havekes LM; Romijn JA
    Endocrinology; 2006 Oct; 147(10):4553-8. PubMed ID: 16709607
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adiponectin mediates the metabolic effects of FGF21 on glucose homeostasis and insulin sensitivity in mice.
    Lin Z; Tian H; Lam KS; Lin S; Hoo RC; Konishi M; Itoh N; Wang Y; Bornstein SR; Xu A; Li X
    Cell Metab; 2013 May; 17(5):779-89. PubMed ID: 23663741
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cholic Acid Supplementation of a High-Fat Obesogenic Diet Suppresses Hepatic Triacylglycerol Accumulation in Mice via a Fibroblast Growth Factor 21-Dependent Mechanism.
    Ippagunta SM; Kharitonenkov A; Adams AC; Hillgartner FB
    J Nutr; 2018 Apr; 148(4):510-517. PubMed ID: 29659970
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 99.